Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models-Reference-Cited by-同舟云学术

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models

Published:2018-08 Issue:4 Volume:11 Page:911-919
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Kumar Sushil,Sun Jessica D.,Zhang Libo^ORCID,Mokhtari Reza Bayat,Wu Bing,Meng Fanying,Liu Qian,Bhupathi Deepthi,Wang Yan,Yeger Herman,Hart Charles,Baruchel Sylvain

Funder

James Fund for Neuroblastoma Research

Threshold Pharmaceutical Inc.

Curtis Chow Memorial Fund

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model;Zhang;Neoplasia,2009

2. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor;Kumar;Clin Cancer Res,2011

3. Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality;McIntyre;EMBO Mol Med,2015

4. Targeting hypoxia in cancer therapy;Wilson;Nat Rev Cancer,2011

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Azobenzene‐Based Linker Strategy for Selective Activation of Antibody–Drug Conjugates;Angewandte Chemie International Edition;2024-03-06

2. Azobenzene‐Based Linker Strategy for Selective Activation of Antibody–Drug Conjugates;Angewandte Chemie;2024-03-06

3. Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration;JCI Insight;2024-01-09

4. Notch signaling, hypoxia, and cancer;Frontiers in Oncology;2023-01-31

5. Predicting response to combination evofosfamide and immunotherapy under hypoxic conditions in murine models of colon cancer;MATH BIOSCI ENG;2023